Nonclinical safety assessment of an mRNA Covid‐19 vaccine candidate following repeated administrations and biodistribution
Journal of Applied Toxicology · 2024-03 · 44 (3) · 371-390
DOI: 10.1002/jat.4548 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Applied Toxicology, online erschienen am 18.09.2023. Verfasst von Karine Broudic und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development, Sanofi, Marcy l'Etoile, France. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Messenger RNA (mRNA) vaccines have demonstrated efficacy against Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) in humans. mRNA technology holds tremendous potential for rapid control and prevention of emergencies due to its flexibility with respect to production, application, and design for an efficacious and safe use in humans. We assessed the toxicity and biodistribution of MRT5500, an mRNA vaccine encoding for the full‐length of the SARS‐CoV‐2 spike protein and delivered by lipid nanoparticles (LNPs) containing a novel ionizable lipid, Lipid‐1 in preclinical animal models. In the repeated dose toxicity study, rabbits received three intramuscular (IM) injections of MRT5500 at 3‐week interval followed by a 4‐week observation period. In an exploratory biodistribution study in mice receiving a single IM injection of an mRNA encoding luciferase encapsulated in an LNP containing Lipid‐1, the expression of the luciferase protein was monitored in vivo and ex vivo at several time points. In the regulatory biodistribution study in rabbits receiving a single IM injection of MRT5500, the quantification of the mRNA and the ionizable Lipid‐1 were monitored in the same organs and time points as in the exploratory biodistribution study. MRT5500 was safe and well‐tolerated with a transient acute phase response/inflammation and an expected vaccine‐related immunological response, typical of those observed following a vaccine administration. The biodistribution data demonstrated that the mRNA and Lipid‐1 components of the vaccine formulations were mainly detected at the injection site and in the draining lymph nodes. These results support the use of MRT5500 and its deployment into clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research and Development, Sanofi, Marcy l'Etoile, France.
- Research and Development, Sanofi, Montpellier Cedex, France.
- France Safety Assessment SAS, Charles River Laboratories, Saint-Germain-Nuelles, France.
ORCID-Profile: Vladimir Perkov, Paul Désert
Zitieren
APA
Broudic, K., Laurent, S., Perkov, V., Simon, C., Garinot, M., Truchot, N., Latour, J., & Désert, P. (2024). Nonclinical safety assessment of an mRNA Covid‐19 vaccine candidate following repeated administrations and biodistribution. Journal of Applied Toxicology, 44(3), 371-390. https://doi.org/10.1002/jat.4548
Vancouver
Broudic K, Laurent S, Perkov V, Simon C, Garinot M, Truchot N, et al. Nonclinical safety assessment of an mRNA Covid‐19 vaccine candidate following repeated administrations and biodistribution. Journal of Applied Toxicology. 2024;44(3):371-390. doi:10.1002/jat.4548
BibTeX
@article{Broudic2024,
author = {Broudic, Karine and Laurent, Sébastien and Perkov, Vladimir and Simon, Charlene and Garinot, Marie and Truchot, Nathalie and Latour, Julie and Désert, Paul},
title = {Nonclinical safety assessment of an mRNA Covid‐19 vaccine candidate following repeated administrations and biodistribution},
journal = {Journal of Applied Toxicology},
year = {2024},
volume = {44},
number = {3},
pages = {371--390},
doi = {10.1002/jat.4548}
}
EUVIMED